Wednesday, 28 October 2020

Gilead Cuts 2020 Sales Outlook As COVID-19 Drug Remdesivir Falls Short

Gilead Sciences Inc on Wednesday cut its 2020 revenue forecast, citing lowerthanexpected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID19.

from Top Business News- News18.com https://ift.tt/3owbcoF
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Beyond Borders: The True Origins Of India's Favorite Brands - Colgate, Bata And Maruti

Bata grew into one of the world's leading shoemakers, with an impressive annual sale of 150 million pairs of shoes across more than 70 c...